UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   FORM 10-QSB

                                   (Mark One)

[ x ]  QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934

                  For the quarterly period ended: June 30, 2007

[  ]    TRANSITION REPORT UNDER SECTION 13 OR 15 (D) OF THE EXCHANGE ACT

                      For the transition period from    to

                         Commission file number 0-17232

                      STEM CELL THERAPY INTERNATIONAL, INC.

        (Exact name of small business issuer as specified in its charter)


                 NEVADA                              88-0374180
       (State or other jurisdiction of      (IRS Employer Identification
        Incorporation or organization)                 Number)


                 2203 N. Lois Avenue, 9th Floor, Tampa, FL 33607

                    (Address of principal executive offices)

                                 (813) 600-4088

                           (Issuer's telephone number)

                                 Not applicable

    (Former name, former address and former fiscal year, if changed since last
                                     report)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.    Yes   [X]   No [ ]


                                        1
<PAGE>
Indicate by check mark whether the registrant is a shell company (as defined by
Rule 12b-2 of the Exchange Act).  Yes [  ]  No  [X]

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the last practicable date:

35,045,369 shares of common stock, $0.001 par value, as of August 13, 2007.

Transitional Small Business Disclosure Format (check one): Yes [  ]  No  [X]


                                        2
<PAGE>
                      STEM CELL THERAPY INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                                TABLE OF CONTENTS

Part I.  Financial Information

Item 1. Financial Statements

Condensed Consolidated  Balance Sheets as of June 30, 2007
     (unaudited) and March 31,  2007                                           5

Condensed Consolidated  Statements of Operations for the three
     months ended June 30,  2007  and  2006  (unaudited)  and
     for the period from December 2, 2004 (Date  of  Inception)
     through  June  30,  2007  (unaudited)                                     6

Condensed Consolidated  Statements of Changes in Stockholders'
     (Deficit) for the period  from  December  2,  2004  (Date
     of Inception) through June 30, 2007 (unaudited)                           7

Condensed Consolidated  Statements of Cash Flows for the three
     months ended June 30,  2007 and 2006 (unaudited),
     for the period from December 2, 2004 (Date of Inception)
     through June 30, 2005                                                     9

Notes to Condensed  Consolidated  Financial  Statements                       10

Item  2.  Management's Discussion and Analysis                                15

Item  3.  Controls and Procedures                                             19

Part II.  Other Information

Item  1.  Legal Proceedings                                                   19

Item  2.  Unregistered Sales of Equity Securities and Use of Proceeds         19

Item  3.  Defaults from Senior Securities                                     19

Item  4.  Submission of Matters to a Vote of Security Holders                 19

Item  5.  Other Information                                                   20

Item  6.  Exhibits                                                            20

Signatures                                                                    23


                                        3
<PAGE>

                          PART I FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and with the instructions for Form 10-QSB and Rule 10-01
of  Regulation S-X.  Accordingly, they do not include all of the information and
footnotes  required  by  generally  accepted  accounting principles for complete
financial  statements.  In the opinion of management, all adjustments considered
necessary  for a fair presentation have been included.  All such adjustments are
of  a  normal  recurring  nature.  Operating results for the three month periods
ended  June 30, 2007 and 2006 are not necessarily indicative of the results that
may  be  expected  for  the year ending March 31, 2008.  For further information
refer to the consolidated financial statements and footnotes thereto included in
the  Company's  Form  10-KSB  filed with the Securities and Exchange Commission.

                                        4
<PAGE>
                      Stem Cell Therapy International Inc.
                         (a development stage enterprise)

                      Condensed Consolidated Balance Sheets


                                                June 30, 2007     March 31, 2007
                                                -------------     --------------
                                                (unaudited)
ASSETS
Current  assets:
     Cash                                      $       5,218     $       27,905
     Inventory                                             -              5,988
     Prepaid  expenses                               177,662             47,317
                                                -------------     --------------
Total  current  assets                               182,880             81,210

Certificate  of  deposit,  restricted                     45              3,919
Prepaid  expenses  and  other  assets                 40,877             53,378
                                                -------------     --------------

               Total  Assets                   $     223,802     $      138,507
                                                =============     ==============

LIABILITIES  AND  STOCKHOLDERS'  DEFICIT
Current  liabilities:
     Accounts  payable                         $     109,014     $       62,875
     Accrued  expenses                               259,953            245,557
     Deferred  revenue                                30,000             50,000
     Stockholder  advances                            48,753             48,753
     Due  to  related  party                         235,200            225,200
                                                -------------     --------------
Total  current  liabilities                          682,920            632,385
                                                -------------     --------------

Commitments and contingencies (Note 6)                     -                  -

Stockholders'  deficit:

     Preferred stock; $.001 par
          value; 10,000,000 shares
          authorized and 500,000
          issued and outstanding                         500                500


     Common stock; $.001 par value;
          100,000,000 shares authorized;
          35,045,369 and 34,495,369
          issued and outstanding as of
          June 30, 2007 and March 31,
          2007, respectively                          35,045             34,495

     Additional  paid-in  capital                    822,025            660,575
     Deficit  accumulated  during
          development  stage                      (1,316,688)        (1,189,448)
                                                -------------     --------------
Total  stockholders'  deficit                       (459,118)          (493,878)
                                                -------------     --------------

     Total liabilities and
          stockholders'  deficit               $     223,802     $      138,507
                                                =============     ==============

The  accompanying  notes  are  an  integral  part  of the condensed consolidated
financial  statements.

                                        5
<PAGE>


                      Stem Cell Therapy International Inc.
                         (a development stage enterprise)

                 Condensed Consolidated Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>


<S>                                       <C>                   <C>              <C>
                                                                                 December 2, 2004
                                                                                 (Date of Inception)
                                          Three Months Ended                     Through June 30,
                                          -------------------------------------
                                          June 30, 2007         June 30, 2006                   2007
                                          --------------------  ---------------  --------------------

Revenue                                   $            20,000   $       25,705   $           446,444
Cost of goods sold:
    General                                            10,268           14,525               236,361
    Loss on firm purchase commitment                        -                -               116,000
                                          --------------------  ---------------  --------------------

Gross margin                                            9,732           11,180                94,083

Operating expenses:
  Selling, general and administrative                 135,411          200,749             1,412,990
                                          --------------------  ---------------  --------------------

Loss from operations                                 (125,679)        (189,569)           (1,318,907)

  Interest (expense) income, net                       (1,561)            (186)                2,219
                                          --------------------  ---------------  --------------------

Net loss before taxes                                (127,240)        (189,755)           (1,316,688)

Income tax expense                                          -                -                     -
                                          --------------------  ---------------  --------------------

Net loss                                             (127,240)        (189,755)           (1,316,688)

Less:  Dividends on preferred stock                         -                -               (10,000)
                                          --------------------  ---------------  --------------------

Loss attributable to common shareholders  $          (127,240)  $     (189,755)  $        (1,326,688)
                                          ====================  ===============  ====================

Loss per share, basic and diluted         $              (.00)  $         (.01)  $             (0.05)
                                          ====================  ===============  ====================

Weighted average number
  of common shares outstanding,
  basic and diluted                                34,650,925       33,813,490            29,253,613
                                          ====================  ===============  ====================
</TABLE>


     The accompanying notes are an integral part of the condensed consolidated
                              financial statements.



                                        6
<PAGE>

                      STEM CELL THERAPY INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
      CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
   FROM DECEMBER 2, 2004 (DATE OF INCEPTION) THROUGH JUNE 30, 2007 (UNAUDITED)

<TABLE>
<CAPTION>
<S>                          <C>          <C>       <C>        <C>      <C>           <C>                  <C>
                             COMMON STOCK           PREFERRED STOCK
                             ---------------------  ------------------
                                                                                      DEFICIT
                                                                                      ACCUMULATED
                                                                        ADDITIONAL    DURING
                                                                        PAID-IN       DEVELOPMENT
                             SHARES       AMOUNT    SHARES     AMOUNT   CAPITAL       STAGE                TOTAL
                             -----------  --------  ---------  -------  ------------  -------------------  -----------
Issuance of common
stock for cash               13,550,000   $13,550           -  $     -  $         -   $                -   $   13,550

Exercise of stock
options for services            500,000       500           -        -            -                    -          500

Issuance of common
stock and options
for acquisition deposit       5,000,000     5,000           -        -        2,749                    -        7,749

Stock options issued
for services                          -         -           -        -          906                    -          906

Issuance of common
stock for services            2,170,000     2,170           -        -            -                    -        2,170

Net loss for the period               -         -           -        -            -              (26,241)     (26,241)
                             -----------  --------  ---------  -------  ------------  -------------------  -----------

Balance, March 31, 2005      21,220,000   $21,220           -  $     -  $     3,655   $          (26,241)  $   (1,366)

Cancellation of common
stock issued and options
awarded for services         (5,600,000)   (5,600)          -        -       (2,749)                   -       (8,349)

Issuance of common
stock for services            8,741,832     8,741           -        -      299,898                    -      308,639

Reverse acquisition,
September 1, 2005             6,310,678     6,311           -        -         (906)                   -        5,405

Issuance of common
stock for a reduction
in shareholder advances       3,000,000     3,000           -        -            -                    -        3,000

Issuance of preferred
stock for cash                        -         -     500,000      500       34,500                    -       35,000

Dividend on preferred stock           -         -           -        -      (10,000)                   -      (10,000)

</TABLE>

                                        7
<PAGE>

                      STEM CELL THERAPY INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (CONTINUED)
   FROM DECEMBER 2, 2004 (DATE OF INCEPTION) THROUGH JUNE 30, 2007 (UNAUDITED)


<TABLE>
<CAPTION>
<S>                          <C>          <C>       <C>        <C>      <C>           <C>                  <C>
                             COMMON STOCK           PREFERRED STOCK
                             ---------------------  ------------------
                                                                                      DEFICIT
                                                                                      ACCUMULATED
                                                                        ADDITIONAL    DURING
                                                                        PAID-IN       DEVELOPMENT
                             SHARES       AMOUNT    SHARES     AMOUNT   CAPITAL       STAGE                TOTAL
                             -----------  --------  ---------  -------  ------------  -------------------  -----------
Net loss for the year
ended March 31, 2006                  -         -           -        -            -             (506,161)   ($506,161)
                             -----------  --------  ---------  -------  ------------  -------------------  -----------

Balance, March 31, 2006      33,672,510   $33,672     500,000  $   500  $   324,398            ($532,402)    (173,832)

Issuance of common
stock for services              822,859       823           -        -      336,177                    -      337,000

Net loss for the year
ended March 31, 2007                  -         -           -        -            -             (657,046)    (657,046)
                             -----------  --------  ---------  -------  ------------  -------------------  -----------

Balance, March 31, 2007      34,495,369   $34,495     500,000  $   500  $   660,575          ($1,189,448)   ($493,878)

Issuance of common
stock for services              550,000       550           -        -      161,450                    -      162,000

Net loss for the three
months ended June
30, 2007                              -         -           -        -            -             (127,240)    (127,240)
                             -----------  --------  ---------  -------  ------------  -------------------  -----------

Balance, June 30, 2007       35,045,369   $35,045     500,000  $   500  $   822,025          ($1,316,688)    (459,118)
                             ===========  ========  =========  =======  ============  ===================  ===========
</TABLE>

   The accompanying notes are an integral part of the condensed consolidated
                             financial statements.


                                        8
<PAGE>
                      Stem Cell Therapy International Inc.
                        (a development stage enterprise)
                 Condensed Consolidated Statements of Cash Flows
                                   (unaudited)

<TABLE>
<CAPTION>


<S>                                          <C>              <C>              <C>
                                                                               December 2, 2004
                                             Three Months     Three Months     (Date of Inception)
                                             Ended            Ended            Through June 30,
                                             June 30, 2007    June 30, 2006    2007
                                             ---------------  ---------------  --------------------
OPERATING ACTIVITIES:
  Net loss                                   $     (127,240)  $     (189,755)  $        (1,316,688)
  Adjustments to reconcile net loss to net
    cash used by operating activities:
    Stock based compensation                         44,156           64,848               606,968
    Investment income reinvested                          -                -                (2,943)
    Amortization                                          -              125                   667
    Write off of intangible asset                         -                -                 4,333
  (Increase) decrease in:
        Inventory                                     5,988                -                     -
        Prepaid expenses                                  -           22,410               (12,318)
        Deposits                                          -                -                (2,169)
  Increase (decrease) in:
        Accounts payable                             46,139           22,419               109,014
        Accrued payroll                              14,396           37,104               184,953
        Accrued expenses                                  -                -                75,000
        Deferred revenue                            (20,000)          24,275                30,000
                                             ---------------  ---------------  --------------------
    Net cash used by operating activities           (36,561)         (18,574)             (323,183)
                                             ---------------  ---------------  --------------------

INVESTING ACTIVITIES:
  Proceeds from (investment in)
  certificate of deposit, restricted                  3,874                -                 2,898
                                             ---------------  ---------------  --------------------
    Net cash provided (used) by
      investing activities                            3,874                -                 2,898
                                             ---------------  ---------------  --------------------

FINANCING ACTIVITIES:
  Proceeds from advances from stockholder                 -              365                52,528
  Payments to stockholder                                 -                -                  (775)
  Advances from related party                        10,000              228               235,200
  Proceeds from sale of stock                             -                -                38,550
                                             ---------------  ---------------  --------------------
    Net cash provided by financing
      activities                                     10,000              593               325,503
                                             ---------------  ---------------  --------------------

NET (DECREASE) INCREASE IN CASH                     (22,687)         (17,981)                5,218
CASH AT BEGINNING OF PERIOD                          27,905           32,642                     -
                                             ---------------  ---------------  --------------------

CASH AT OF END OF PERIOD                     $        5,218   $       14,661   $             5,218
                                             ===============  ===============  ====================

    Cash paid for interest                   $        1,572   $            -   $             3,235
                                             ===============  ===============  ====================

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES:

    Common stock issued for a reduction
             in advance from shareholder     $            -   $            -   $             3,000
                                             ===============  ===============  ====================
   Common stock issued for purchase of
            intangible assets                $            -   $            -   $             5,000
                                             ===============  ===============  ====================
</TABLE>



     The accompanying notes are an integral part of the condensed consolidated
                              financial statements.

                                        9
<PAGE>

                      Stem Cell Therapy International, Inc.
                        (a development stage enterprise)
              Notes to Condensed Consolidated Financial Statements
              Three Months Ended June 30, 2007 and 2006 (unaudited)
            and the period from December 2, 2004 (Date of Inception)
                       through June 30, 2007 (unaudited)

1.     BACKGROUND  INFORMATION  AND  BASIS  OF  PRESENTATION

Company Background

Stem  Cell  Therapy  International,  Inc.  (the  "Company"),  was  originally
incorporated  in  the state of Nevada on December 28, 1992 as Arklow Associates,
Inc.  The Company's operating business. The Company's operating business is Stem
Cell Therapy International Corp. ("Stem Cell Florida") a wholly owned subsidiary
which  is  a  development  stage  enterprise and was incorporate in the state of
Nevada  on December 2, 2004. To date, the Company's activities have been limited
to  raising capital, organizational matters, and the structuring of its business
plan.  The  corporate  headquarters  is  located  in  Tampa,  Florida.

The  Company  is  engaged in the licensing of stem cell technology, the sales of
stem  cell  products, and information, education, and referral services relating
to potential stem cell therapy patients. The Company manufactures allo stem cell
biological  solutions that are currently being used in the treatment of patients
suffering  from  degenerative  disorders  of the human body such as Alzheimer's,
Parkinson's  Disease,  ALS,  leukemia,  muscular  dystrophy, multiple sclerosis,
arthritis,  spinal cord injuries, brain injury, stroke, heart disease, liver and
retinal  disease,  diabetes  as well as certain types of cancer. The Company has
established  agreements  with highly specialized, professional medical treatment
facilities around the world in locations where stem cell transplantation therapy
is approved by the appropriate local government agencies. The Company intends to
provide  these  biological solutions containing stem cell products in the United
States  to  universities,  institutes and privately funded laboratory facilities
for  research  purposes  and  clinical trials. Its products, which are available
now,  include various allo stem cell biological solutions (containing human stem
cells),  low-molecular  proteins  and  human growth factor hormones. The Company
intends  to  deliver  stem  cell transplants worldwide, educate and consult with
physicians  and  patients  in the clinical aspects of stem cell transplantation.

Business  reorganization:

Effective September 1, 2005, Stem Cell Florida entered into a Reorganization and
Stock  Purchase  Agreement  (the  "Agreement")  with  the  Company,  then  named
Altadyne,  Inc.,  a  company  quoted  on  the  Pink Sheets, which had no assets,
liabilities  or  ongoing  operations.  Under  the  terms  of  the agreement, the
Company,  (then  Altadyne) acquired 100% of the issued and outstanding shares of
common  stock  of  Stem  Cell  Florida  in  a non-cash transaction and Stem Cell
Florida  became  a  wholly  owned  subsidiary  of the Company. Subsequent to the
merger,  Altadyne  changed its name to Stem Cell Therapy International Inc. This
transaction is accounted for as a reverse merger, with Stem Cell Florida treated
as  the  accounting  acquirer  for  financial  statement  purposes.

The  results  of  operations for Stem Cell Florida, the accounting acquirer, for
the  period  from December 2, 2004 (Date of Inception) have been included in the
consolidated  statements  of  operations  of  the  Company.


                                       10
<PAGE>
                      Stem Cell Therapy International, Inc.
                        (a development stage enterprise)
              Notes to Condensed Consolidated Financial Statements
              Three Months Ended June 30, 2007 and 2006 (unaudited)
            and the period from December 2, 2004 (Date of Inception)
                       through June 30, 2007 (unaudited)

1.     BACKGROUND  INFORMATION  AND  BASIS  OF  PRESENTATION  (CONTINUED):

Basis of presentation:

In the opinion of management, the accompanying consolidated financial statements
include  all  adjustments,  consisting only of normal recurring items, necessary
for  their  fair  presentation  in conformity with generally accepted accounting
principles.  The  results of operations for the three months ended June 30, 2007
are  not  necessarily  indicative  of  the  results  for  a  full  year.

The  year-end  condensed  balance  sheet data was derived from audited financial
statements,  but  does  not  include  all  disclosures  required  by  accounting
principals  generally  accepted  in  the  United  States  of  America.

The  condensed  consolidated  financial statements for the period ended June 30,
2007  and  notes  thereto  should  be  read in conjunction with the consolidated
financial  statements  and  notes  thereto  for the year ended March 31, 2007 as
filed  in  the Form 10-KSB, filed with the Securities and Exchange Commission on
July  16,  2007.

Principles of consolidation:

The accompanying consolidated financial statements include the accounts of Stem
Cell Therapy International, Inc. and its wholly-owned subsidiary, Stem Cell
Therapy International Corp.  All intercompany accounts and transactions have
been eliminated.

2.     LIQUIDITY  AND  MANAGEMENT'S  PLANS:

The  accompanying  consolidated financial statements have been prepared assuming
that  the  Company will continue as a going concern.  For the three months ended
June  30, 2007 and the period since December 2, 2004 (date of inception) through
June  30,  2007,  the  Company  has  had  net losses of $127,240 and $1,316,688,
respectively  and cash used by operations of $36,561 and $323,183, respectively,
and negative working capital of $500,040 at June 30, 2007.  As of June 30, 2007,
the  Company  has  not  emerged  from  the  development stage.  In view of these
matters,  the ability of the Company to continue as a going concern is dependent
upon  the  Company's  ability  to  generate  additional financing and ultimately
increase  operations  and  to achieve a level of profitability. Since inception,
the  Company  has  financed  its  activities  principally from the use of equity
securities  to  pay for services and related party advances. The Company intends
on  financing  its  future  development activities and its working capital needs
largely  from  the  sale of equity securities, debt financing and loans from the
Company's  Chief  Executive  Officer,  until  such  time  that funds provided by
operations  are sufficient to fund working capital requirements. There can be no
assurance  that  the Company will be successful at achieving its financing goals
at  reasonably  commercial  terms,  if  at  all.

3.     SIGNIFICANT  ACCOUNTING  POLICIES:

Adoption  of  FASB  Interpretation  No.  48:

Effective  April  1, 2007, the Company adopted the accounting provisions of FASB
Interpretation  No.  48,  Accounting for Uncertainties in Income Taxes (FIN 48).
FIN  48  clarifies  the  accounting  for uncertainty in income taxes recognized,
prescribes  a  recognition  threshold  and  measurement  attribute for financial
statement  recognition  of  tax  positions  taken or expected to be taken by the
Company  in  its income tax returns.  The Company recognizes income taxes on tax
positions  which  have  not been considered more-likely-than-not to be sustained
upon  examination,  including  resolution  of  any related appeals or litigation
processes,  based on the technical merits of the positions.  The tax position is
measured at the largest amount of benefit that is greater than 50 percent likely
of  being  realized  upon  ultimate  settlement.

                                       11
<PAGE>
                      Stem Cell Therapy International, Inc.
                        (a development stage enterprise)
              Notes to Condensed Consolidated Financial Statements
              Three Months Ended June 30, 2007 and 2006 (unaudited)
            and the period from December 2, 2004 (Date of Inception)
                       through June 30, 2007 (unaudited)

4.     EQUITY:

The  Company  has  100,000,000  shares of common stock authorized.  In addition,
there  are  10,000,000  authorized shares of participating convertible preferred
stock,  $.001  par  value,  the  issuance of which is subject to approval by the
Board  of  Directors.  The  Board  of  Directors  has  the  authority to declare
dividends.  The  voting  rights  of  the  convertible preferred stockholders are
equivalent  to that of the common stockholders.  The convertible preferred stock
can  be  converted at any time by the holder into one share of common stock.  As
of  June 30, 2007, the Company had 500,000 shares of convertible preferred stock
issued  and  outstanding.  Management  determined that the convertible preferred
stock  contained  a  beneficial  conversion  feature  based  on  the  effective
conversion  price  and  the  fair value of the convertible preferred stock.  The
beneficial  conversion was recorded in an amount equal to the difference between
the calculated fair value and the book value, which was $10,000 and was recorded
as  additional  paid in capital and interest expense, as the preferred stock can
be  converted  at  any  time  after  the  issue  date.

During  the  three months ended June 30, 2007, the Company issued 250,000 shares
of  common  stock  valued  at $45,000, in exchange for consulting services to be
provided through August 11, 2007.  As of June 30, 2007, the Company has included
$22,500  in  prepaid expenses.  The Company also issued 300,000 shares of common
stock valued at $117,000 for consulting services to be provided through December
25,  2007.  As  of  June  30, 2007, the Company has included $117,000 in prepaid
expenses.

5.     INCOME TAXES

The Company adopted the provisions of FASB Interpretation No. 48, Accounting for
Uncertainties  in  Income  Taxes  (FIN  48).  FIN  48,  on  April  1,  2007. The
implementation  of  FIN No. 48 had no effect on the Company's financial position
or results of operations. The Company classifies interest and penalties incurred
on  tax  deficiencies  in  interest  expense  and  other  expense, respectively.

Taxes  on  income  are  provided in accordance with SFAS No. 109, Accounting for
Income  Taxes. Deferred income tax assets and liabilities are recognized for the
expected  future  tax  consequences  of  events  that have been reflected in the
consolidated  financial  statements.  Deferred  tax  assets  and liabilities are
determined based on the differences between the book values and the tax bases of
particular  assets and liabilities and the tax effects of net operating loss and
capital  loss  carry  forwards. Deferred tax assets and liabilities are measured
using  enacted  tax  rates  expected  to apply to taxable income in the years in
which  those  temporary differences are expected to be recovered or settled. The
effect  on  deferred  tax  assets and liabilities of a change in the tax rate is
recognized  as income or expense in the period that included the enactment date.
The Company has incurred operating losses since its inception and, therefore, no
tax  liabilities  have  been  incurred  for the periods presented. The amount of
unused tax losses available to carry forward and apply against taxable income in
future  years  totaled approximately $1,130,000 at June 30, 2007. The loss carry
forwards  expire  beginning  in  2025.  Internal  Revenue  Code  Sec. 382 places
limitations  on  the utilization of net operating losses.  Due to the limitation
the  Company  has  placed  a  full  valuation  allowance  against  that asset of
approximately  $494,300.

The income tax provision differs from the amount of tax determined by applying
the Federal statutory rate as follows:

                                                               Period from
                                                               December 2,
                             Three Months Ended                2004 through
                             --------------------------------
                             June 30, 2007    June 30, 2006    June 30, 2007
                             ---------------  ---------------  ---------------
Income tax provision
at statutory rate                  ($43,262)        ($65,077)       ($404,412)
Increase (decrease) in
income tax due to:
    Nondeductible expenses              481                -              670
    State income taxes, net          (4,619)          (6,307)         (43,177)
    Change in valuation
    allowance                        47,400           71,384          446,919
                             ---------------  ---------------  ---------------
                             $            0   $            0   $            0
                             ===============  ===============  ===============

                                       12
<PAGE>
                      Stem Cell Therapy International, Inc.
                        (a development stage enterprise)
              Notes to Condensed Consolidated Financial Statements
              Three Months Ended June 30, 2007 and 2006 (unaudited)
            and the period from December 2, 2004 (Date of Inception)
                       through June 30, 2007 (unaudited)

5.     INCOME  TAXES  (CONTINUED)

There  was  no current or deferred provision or benefit for income taxes for the
three  months  ended  June 30, 2007 and 2006 and for the period from December 2,
2004  (Date of Inception) through June 30, 2007.  The components of deferred tax
assets  as  of  June  30,  2007  and  March  31,  2007:

                                   June 30, 2007    March 31, 2007
                                   ---------------  ----------------
Deferred tax (liability) asset:
  Accrued payroll                  $       68,300   $        64,200
  Net operating loss carryforward         426,000           382,700
                                   ---------------  ----------------
                                          494,300           446,900
  Valuation allowance                    (494,300)         (446,900)
                                   ---------------  ----------------
  Total deferred taxes             $            0   $             0
                                   ===============  ================

Income taxes are based on estimates of the quarterly effective tax rate and
evaluations of possible future events and transactions and may be subject to
subsequent refinement or revision.

6.     COMMITMENTS  AND  CONTINGENCIES

Consulting  agreements:

The  Company has entered into several consulting agreements with other companies
and individuals to provide consulting and advisory services to the Company.  The
agreements provide for terms ranging from one to three years.  Additionally, the
consulting agreements required the issuance of 4,789,000 shares of the Company's
common  stock  valued at $544,409 on the date of the agreement as the shares are
non-forfeitable and non-cancelable.  As of June 30, 2007, the Company had issued
these  shares  of common stock and has included $216,208 in prepaid expenses for
services  not  yet  performed  pursuant  to  the  agreements.

Effective  May  4,  2005, the Company entered into an agreement with Westminster
Securities  Corporation  (Westminster)  for  consulting  services  and to secure
funding  and/or  lines  of  credit.  In exchange for these services, the Company
paid  Westminster  a  $20,000  retainer  and  will  pay  10% of any equity-based
funding,  8%  of  any  debt-based  convertible funding, 5% of any nonconvertible
debt-based  funding,  as  well  as, issue warrants equal to 10% of the number of
shares  of stock issued in connection with the funding.  As of June 30, 2007, no
funding has been secured, however, Westminster did facilitate the acquisition of
Altadyne,  and  therefore  received  379,000 shares of common stock in September
2005.

Licensing  agreement:

Effective  September  1,  2005,  the  Company  entered into a ten year licensing
agreement  with  the  Institute  of  Cell  Therapy,  a  company incorporated and
organized  under  the  laws of Kiev, Ukraine ("ICT"). Pursuant to the agreement,
the  Company  issued ICT 5,000,000 shares of the Company's common stock recorded
at  the fair market value of the Company's common stock of $5,000. The agreement
grants  the  Company  a  right and license in most parts of the world to utilize
patents,  processes and products owned or produced by ICT in connection with the
operation  of  the  Company's business. In exchange for the license, the Company
agrees  to  exclusively  purchase  all  biological  solution  of  stem cell Allo
Transplant materials from ICT. Such Allo Transplant materials shall be at a cost
of  $6,500  per  patient  per  condition.  The  licensing agreement guarantees a
minimum  purchase  of 60 portions per twelve month period. In the event that the
Company  is  unable  to purchase the minimum quantities, ICT will be entitled to
draw  upon  the  irrevocable  letter  of  credit at the rate of $2,000 for every
portion  less  than  the minimum required purchase. The Company had provided ICT
with  a $120,000 irrevocable letter of credit in ICT's favor for the first three
years  of  the  agreement.  In the event the Letter of Credit is drawn upon, the
Company  agreed  to  replenish  the  Letter  of Credit to the extent of any such
draws.  As  of  September 2006, the Company had not met the first year's minimum
purchase  requirement  and  ICT withdrew $116,000 on the letter of credit, which
has  been  included  in  the cost of goods sold in the accompanying Consolidated
Statements  of  Operations  for the period from inception through June 30, 2007.
However,  ICT was unable to provide the product as requested and the Company was
required  to  purchase  the

                                       13
<PAGE>
                      Stem Cell Therapy International, Inc.
                        (a development stage enterprise)
              Notes to Condensed Consolidated Financial Statements
              Three Months Ended June 30, 2007 and 2006 (unaudited)
            and the period from December 2, 2004 (Date of Inception)
                       through June 30, 2007 (unaudited)

6.     Commitments and Contingencies (continued)

stem  cell  materials  from alternative sources.  Management believes that ICT's
inability  to  provide the requested stem cell materials relieves the Company of
its  obligations  to  replenish  the letter of credit and to fulfill the minimum
purchase  requirements.  As  such,  the  accompanying  consolidated  financial
statements  do  not  reflect any liability for the Company's failure to purchase
the  minimum  amount  of  stem  cell materials under the above mentioned license
agreement.

Financing  agreements:

During  the  year ended March 31, 2007, the Company entered into an agreement to
locate  financing with a third party for three years. As consideration for these
consulting  services,  the  Company  has  agreed  to  issue  500,000  shares  of
restricted  common  stock  and a 10% finder's fee for any funds brought into the
Company.  As  of  June  30,  2007,  the Company has not entered into any funding
agreements,  and  therefore  the  third  party  is  not  owed any consideration.

Effective  June  27,  2007, the Company entered into an agreement with Newbridge
Securities,  Corp. ("Newbridge") to assist the Company on a "best efforts" basis
in  raising  approximately  $250,000  in  a  private offering of up to 2 million
shares  of  restricted common stock at a price of $.125 per share.  Newbridge is
entitled to a selling concession of 10% of the gross proceeds of the offering, a
3%  non-accountable  expense  allowance and warrant coverage equal to 20% of the
total  securities  placed  in  the offering, including any penalty shares, at an
exercise  price  of  $.15  per  share.  The  Company  is  required  to  file  a
registration  statement  covering  the  above  securities  within 45 days of the
completion  of  the  offering.  If  the  Company  fails to have the registration
statement  deemed effective by the Securities and Exchange Commission within 135
days after the completion of the offering, the Company will issue to the holders
of the securities, additional shares of restricted common stock equal to 1.5% of
the number of shares purchased for each thirty-day period until the registration
statement is deemed effective, up to a maximum of eight such thirty-day periods.

Subsequent  to  June  30,  2007,  Newbridge  assisted  the  Company  in  raising
approximately  $226,000  of  proceeds  from  a  private  placement  offering.



                                       14
<PAGE>
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

THE  FOLLOWING  INFORMATION  SHOULD  BE  READ  IN CONJUNCTION WITH THE CONDENSED
CONSOLIDATED  FINANCIAL  STATEMENTS OF STEM CELL THERAPY INTERNATIONAL, INC. AND
THE  NOTES  THERETO  APPEARING  ELSEWHERE  IN  THIS  FILING.  STATEMENTS IN THIS
MANAGEMENT'S  DISCUSSION AND ANALYSIS OR PLAN OF OPERATION AND ELSEWHERE IN THIS
FILING  ON  FORM  10-QSB  THAT  ARE NOT STATEMENTS OF HISTORICAL OR CURRENT FACT
CONSTITUTE  "FORWARD-LOOKING  STATEMENTS."

                                GENERAL OVERVIEW

     Stem  Cell  Therapy  International,  Inc.  (the  "Company")  was originally
incorporated  in  Nevada  on  December  28, 1992 as Arklow Associates, Inc., and
after  several  name  changes  was  renamed  Altadyne,  Inc. By March, 2005, the
Company  (then  Altadyne, Inc.) had no assets, liabilities, or ongoing business.
On  March  20, 2005, R Capital Partners ("R Capital") acquired the Company (then
Altadyne, Inc.), and on September 1, 2005, the Company (then Altadyne), acquired
Stem  Cell  Therapy  International  Corp.,  a  Nevada  corporation  ("Stem  Cell
Florida")  in  what  was  effectively  a  reverse  acquisition.  Following  the
transaction,  Stem Cell Florida became a wholly owned subsidiary of the Company,
and  Stem  Cell  Florida's  shareholders  became shareholders of the Company. On
October  5,  2005,  the  Company  changed  its  name  to  Stem  Cell  Therapy
International, Inc. to reflect the new business of the Company. This transaction
is  accounted  for  as  a  reverse merger, with Stem Cell Florida treated as the
accounting  acquirer  for  financial  statement  purposes.

     Stem Cell Florida was incorporated in Nevada on December 2, 2004. Following
the reverse acquisition, the Company assumed and is continuing the operations of
Stem  Cell  Florida. The Company's executive management team are: Calvin C. Cao,
Chairman  and  Chief  Executive  Officer,  Daniel  J.  Sullivan, Chief Financial
Officer, and Lixian Jiang, Chief Operating Officer and Patent Trademark Counsel.

     We  are indirectly involved, as a "middle man," in research and development
and  practical application within the field of regenerative medicine. We provide
allo (human) stem cell biological solutions that are currently being used in the
treatment  of  patients suffering from degenerative disorders of the human body.
We  have  established  agreements  with highly specialized, professional medical
treatment  facilities  around  the  world  in  locations  where  Stem  Cell
Transplantation  therapy  is  approved  by  the  appropriate  local  government
agencies.

     We  intend  to provide these biological solutions containing allo stem cell
products  also  in  the  United States to universities, institutes and privately
funded  laboratory  facilities  for  research  purposes  and  clinical  trials.

     We  will  initially devote most of our efforts toward organization and fund
raising  for  planned  clinics  and patient operations and limited revenues have
been  generated  from any such operations. The Company has experienced recurring
losses  from  operations  since  its  inception

                                       15
<PAGE>
and  at  June  30,  2007,  we  had  a working capital deficit of $500,040 and an
accumulated  deficit  from operations of $1,316,668. As noted in the independent
audit  report  for  the  audited Stem Cell Therapy International, Inc. financial
statements  for the period from inception to March 31, 2007, these factors raise
doubt  about  the  ability  of  the  Company  to  continue  as  a going concern.
Realization  of  the  Company's  business  plan  is dependent upon the Company's
ability  to  meet  its  future financing requirements, and the success of future
operations.  This  is  because  we have not generated substantial revenues since
inception. Our only other source for cash at this time is through investments or
loans  from  management. We must raise cash to implement our project and stay in
business.

                          CRITICAL ACCOUNTING POLICIES

     The  accounting  policies  of  the Company are in accordance with generally
accepted  accounting principles of the United States of America, and their basis
of  application  is  consistent.  Outlined  below  are those policies considered
particularly  significant:

     The  preparation  of  financial  statements  in  conformity with accounting
principles  generally  accepted  in  the  United  States  of  America  requires
management to make estimates and assumptions that affect the reported amounts of
assets  and  liabilities  and disclosure of contingent assets and liabilities at
the  date  of  the financial statements and the reported amounts of revenues and
expenses  during  the  reporting  period. Actual results could differ from those
estimates.

     Common  stock  transactions  for  services  are recorded at either the fair
value  of the stock issued or the fair value of the services rendered, whichever
is  more evident on the day that the transactions are executed. The certificates
must  be  issued  subsequent  to  the  transaction  date.

     We  apply Staff Accounting Bulletin No. 104 "Revenue Recognition" ("SAB No.
104")  to  our  revenue  arrangements.  Currently, our only revenue transactions
derive  from  providing informational and referral services; we have no plans to
enter  into any other revenue transaction in the near future. In accordance with
SAB  No.  104, we recognize revenue related to these services upon rendering the
services, as long as (1) there is persuasive evidence of an arrangement, (2) the
sales  price  is  fixed  or  determinable,  and  (3)  collection  of the related
receivable is reasonably assured. Any payments received prior to delivery of the
products  or  services  are included in deferred revenue and recognized once the
products  are  delivered  or  the  services  are  performed.

     Research  and development costs are charged to operations when incurred and
are  included  in  operating  expenses.

                              RESULTS OF OPERATIONS

As of June 30, 2007 and for the three months ended June 30, 2007 and 2006

     We  had  revenue  of $20,000 during the three months ended June 30, 2007 as
compared  to  $25,705  of  revenue  for the comparable period in 2006.  Revenues
during  2007  reflected  the

                                       16
<PAGE>
treatment of one patient whereas there were two patients treated during the same
period  ended  2006.

     Our  cost  of  goods  sold  for the stem cell biological material delivered
during  the  three months ended June 30, 2007 was $10,268 as compared to $14,525
for  the  same  period ended 2006.  The decrease in cost of goods sold is due to
the  decrease in patient treatments in 2007 compared to the same period in 2006.

     Gross  margins for the three months ended June 30, 2007 was 49% compared to
43%  for  the three months ended June 30, 2006.  The increase in gross margin is
due  to  the  Company  purchasing  the  stem cell biological materials from less
expensive  vendors.

     Selling,  general  and  administrative expenses decreased $65,338 or 33% to
$135,411  for  the  three months ended June 30, 2007 as compared to $200,749 for
the  three  months  ended  June  30, 2006.  The decrease in selling, general and
administrative  expenses  for  the three months ended June 30, 2007 is primarily
due  to  an approximate $72,000 decrease in professional fees as the Company has
not  yet  renewed the doctor's consulting agreements and is not entering into as
many  investor relations and finance consulting agreements as in the prior year.
The  decrease  is  also  due  to the decrease of approximately $6,000 in payroll
expenses.  The  decrease  in  payroll expenses is due to the loss of an employee
during  the  year ended March 31, 2007.  These decreases are partially offset by
an increase of approximately $6,000 in research and development costs and $3,400
increase  in  travel  and  entertainment  expenses.

     Our  net  loss  for  the  three  months ended June 30, 2007 was $127,240 as
compared to $189,755 during the same period in 2006. The loss primarily reflects
decreases  in  professional  fees  and  payroll  expenses.

LIQUIDITY AND CAPITAL RESOURCES

     The  Company's  financial  statements  have been prepared assuming that the
Company  will  continue  as a going concern. For the three months ended June 30,
2007  and the period since December 2, 2004 (date of inception) through June 30,
2007,  the  Company  has had a net loss of $127,240 and $1,316,688, respectively
and  cash used by operations of $36,561 and $323,183, respectively, and negative
working  capital  of  $500,040  at  June  30,  2007.

     As  of  June  30,  2007,  the  Company has not emerged from the development
stage.  In view of these matters, recoverability of recorded asset amounts shown
in the accompanying financial statements is dependent upon the Company's ability
to  begin  significant operations and to achieve a level of profitability. Since
inception,  the Company has financed its activities principally from shareholder
advances  and  some  relatively  minor  sales of equity securities (as set forth
below).  The  Company intends on financing its future development activities and
its  working capital needs largely from the sale of equity securities until such
time  that  funds  provided by operations are sufficient to fund working capital
requirements.

     Effective  June  27,  2007,  the  Company  entered  into  an agreement with
Newbridge  Securities,  Corp.  ("Newbridge")  to  assist  the Company on a "best
efforts"  basis  in  raising

                                       17
<PAGE>
approximately  $250,000  in  a  private  offering  of  up to 2 million shares of
restricted  common  stock  at  a  price  of  $.125  per  share.

     Subsequent  to  June  30,  2007,  the  Company  has  received approximately
$226,000  of  proceeds  from  the  private  placement  offering.

Unpredictability  of  future  revenues;  Potential  fluctuations  in  quarterly
operating  results;  Seasonality

     As a result of our limited operating history and the emerging nature of the
biotechnological  markets  in  which  we  compete,  we  are unable to accurately
forecast  future  revenues.  Our  current  and  future  expense levels are based
largely  on  our  investment plans and estimates of future revenues and are to a
large  extent  fixed  and  expected  to  increase.

     Sales  and  operating  results generally depend on the volume of, timing of
and ability to fulfill the number of orders received for the biological solution
and  the  number of patients treated which are difficult to forecast.  We may be
unable  to  adjust  spending in a timely manner to compensate for any unexpected
revenue  shortfall.  Accordingly,  any  significant  shortfall  in  revenues  in
relation  to  our planned expenditures would have an immediate adverse effect on
our  business,  prospects,  financial  condition  and  results  of  operations.
Further,  as  a strategic response to changes in the competitive environment, we
may from time to time make certain pricing, service or marketing decisions which
could  have  a  material  adverse  effect  on our business, prospects, financial
condition  and  results  of  operations.

     We  expect  to  experience significant fluctuations in our future quarterly
operating  results  due  to  a variety of factors, many of which are outside our
control.  Factors  that  may  adversely  affect  our quarterly operating results
include  (i)  our ability to retain existing patients, attract new patients at a
steady  rate  and  maintain patient satisfaction, (ii) our ability to manage our
affiliated  production  facility  and  maintain  gross  margins,  (iii)  the
announcement or introduction of new treatments and/or patents by the Company and
its  competitors,  (iv) price competition or higher  prices in the industry, (v)
the  level  of  use  of  the  Internet  and  on-line  patient services, (vi) the
Company's  ability  to  upgrade  and  develop its systems and infrastructure and
attract  new  personnel  in  a  timely  and effective manner, (vii) the level of
traffic on our website, (viii) technical difficulties, system downtime, (ix) the
amount  and  timing  of  operating  costs  and  capital expenditures relating to
expansion  of  our  business,  operations  and  infrastructure, (x) governmental
regulation,  and  (xi)  general  economic  conditions.

OFF-BALANCE  SHEET  ARRANGEMENTS

     The Company is not currently engaged in any off-balance sheet arrangements,
as  defined by Item 303(c)(2) of Regulation S-B.  The Company has not engaged in
any  off-balance  sheet  arrangement  during  the  last  fiscal year, and is not
reasonably  likely  to  engage  in any off-balance sheet arrangement in the near
future.


                                       18
<PAGE>
ITEM 3.  CONTROLS AND PROCEDURES

     As required by Rule 13a-15 under the Securities Exchange Act of 1934 (the
"Exchange Act"), as of June 30, 2007, the Company carried out an evaluation of
the effectiveness of the design and operation of the Company's disclosure
controls and procedures.  This evaluation was carried out under the supervision
and with the participation of the Company's management, including the Company's
Chief Financial Officer (who has served as the principal financial and
accounting officer) and its President (who serves as the principal operating
officer).  Based upon that evaluation, the Company's President and Chief
Financial Officer have concluded that the Company's disclosure controls and
procedures are effective in alerting them to material information regarding the
Company's financial statement and disclosure obligation in order to allow the
Company to meet its reporting requirements under the Exchange Act in a timely
manner.

     The Company's management, with the participation of its President and Chief
Financial Officer, has determined that there has been no change in the Company's
internal control over financial reporting that occurred during the Company's
last fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the Company's internal control over financial reporting.

                           PART II - OTHER INFORMATION

ITEM 1.   LEGAL PROCEEDINGS

None

ITEM 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

     Effective  May  11, 2007, the Company issued 250,000 shares of common stock
to  Mirador  Consulting  Group  in  connection  with  consulting  services to be
provided  to  the Company.  These shares were issued without any public offering
in  accordance  with  Section  4(2)  of  the Securities Act of 1933, as amended.

     Effective  June 25, 2007, the Company issued 300,000 shares of common stock
to Interactive Resources Group Inc. in connection with consulting services to be
provided  to  the Company.  These shares were issued without any public offering
in  accordance  with  Section  4(2)  of  the Securities Act of 1933, as amended.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

                                       19
<PAGE>
ITEM 5.  OTHER INFORMATION

Not Applicable.

ITEM 6.   EXHIBITS AND REPORTS ON FORM 8-K

(a)  Exhibit  Index.  The  following  exhibits are filed with or incorporated by
     reference  into  this  quarterly  report:

3.1  Articles  of  Incorporation  of  Stem  Cell Therapy International, Inc., as
     amended*

3.2  Articles  of  Incorporation  of  Stem  Cell  Therapy  Corp.*

3.3  Certificate  of  Designation  of  Series  A  Preferred  Stock*

3.4  By-laws  of  Stem  Cell  Therapy  International,  Inc.*

10.1 Business  Consulting  and  Services Agreement dated as of December 16, 2004
     between  Stem  Cell  Therapy  International  Corp.  and  PMS  SA.*

10.2 Consulting  Agreement dated as of January 4, 2005 between Stem Cell Therapy
     International  Corp.  and  RES  Holdings  Corp.*

10.3 Investor and Media Relations Contract dated as of February 10, 2005 between
     Stem  Cell  Therapy  International  Corp.  and  Stern  &  Co.*

10.4 Executive  Suite Lease Agreement dated as of February 15, 2005 between Stem
     Cell  Therapy  International  Corp.  and  Wilder  Corporation.*

10.5 Engagement  Letter  dated  as  of  May  3,  2005  between  the  Company and
     Westminster  Securities  Corporation.*

10.6 Reorganization  and  Stock Purchase Agreement dated as of September 1, 2005
     between  the Company (then Altadyne, Inc.), Stem Cell Therapy International
     Corp.  and  R  Capital  Partners,  Inc.*

10.7 Licensing  Agreement  dated as of September 1, 2005 between the Company and
     Institute  of  Cell  Therapy.*

10.8 Consulting  Agreement dated as of September 1, 2005 between the Company and
     European  Consulting  Group,  LLC.*

10.9 Consulting  Agreement dated as of September 1, 2005 between the Company and
     Global  Management  Enterprises,  LLC.*

                                       20
<PAGE>
10.10 Consulting Agreement dated as of September 1, 2005 between the Company and
     USA  Consulting  Group,  LLC.*

10.11 Professional  Services Agreement dated as of September 7, 2005 between the
     Company  and  Bridgehead  Group  Limited,  Inc.*

10.12 Public  Relations  Agreement  dated  as  of September 19, 2005 between the
     Company  and  Stern  &  Co.*

10.13 Advisory  Physician  Agreement  dated  as  of  October 4, 2005 between the
     Company  and  Alexey  Bersenev.*

10.14 Medical and Scientific Advisory Board Member Agreement dated as of October
     10,  2005,  between  the  Company  and  Dr.  Weiwen  Deng.*

10.15 Medical and Scientific Advisory Board Member Agreement dated as of October
     24,  2005,  between  the  Company  and  Dr.  Jorge  Quintero.*

10.16 Medical and Scientific Advisory Board Member Agreement dated as of October
     24,  2005,  between  the  Company  and  Dr.  Salvador  Vargas.*

10.17 Medical  and  Scientific  Advisory  Board  Member  Agreement  dated  as of
     December  2,  2005  between  the  Company  and  Dr.  Igor  Katkov.*

10.18 Medical  and  Scientific  Advisory  Board  Member  Agreement  dated  as of
     December  2,  2005,  between  the  Company  and  Dr.  Nikita  Tregubov.*

10.19 Business Advisory Board Agreement dated as of December 5, 2005 between the
     Company  and  Fred  J.  Villella.*

10.20 Business  Development  Advisory  Agreement  dated  as  of  January 1, 2006
     between  the  Company  and  Alexander  Kulik.*

10.21 Termination  and  Modification  of Engagement Letter dated January 4, 2006
     between  the  Company  and  Westminster  Securities  Corporation.*

10.22 Business  Consulting and Services Agreement dated January 20, 2006 between
     the  Company  and  Julio  C.  Ferreira  dba  Sphaera  Inte-Par.*

10.23 Business  Development  Advisory  Agreement  dated  as  of February 7, 2006
     between  the  Company  and  Gus  Yepes.*

10.24 Medical  and  Scientific Advisory Board Member Agreement dated as of April
     5,  2006  between  the  Company  and  Dr.  Nicholas  Kipshidze,  M.D.*

                                       21
<PAGE>
10.25 Treating  Physician  Agreement  dated  as  of October 24, 2005 between the
     Company  and  Dr.  Salvador  Vargas.*

10.26 Treating  Physician  Agreement  dated  as  of October 24, 2005 between the
     Company  and  Dr.  Jorge  Quintero.*

10.27 Consulting Agreement dated as of June 9, 2006 between the Company and Rick
     Langley.**

10.28 Patient Treatment Agreement dated November 1, 2006 between the Company and
     Shenzhen  Beike  Biotechnology  Company  Limited.**

10.29 Consulting  Agreement dated as of October 12, 2006 between the Company and
     SOS  Resource  Services,  Inc.**

10.30 Newbridge  Securities  Agreement

21.  List of  Subsidiaries

31.1 Chief Executive  Officer  certification  pursuant  to  Section  302  of the
     Sarbanes-Oxley  Act  of  2002.

31.2 Chief Financial  Officer  certification  pursuant  to  Section  302  of the
     Sarbanes-Oxley  Act  of  2002.

32.1 Chief Executive  Officer  certification  pursuant to 18 U.S.C. Section 1350

32.2 Chief Financial  Officer  certification  pursuant to 18 U.S.C. Section 1350

_______________________

* Previously filed with the Company's initial filing of this Registration
Statement on Form 10-SB, file number 000-51931, filed on April 25, 2006, and
incorporated by this reference as an exhibit.
**Previously filed with the Company's annual report on Form 10-KSB filed on July
16, 2007, and incorporated by this reference as an exhibit.


(b) Reports on Form 8-K.
    --------------------

None

                                       22
<PAGE>
                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Date: August 14, 2007

By:    /s/Calvin Cao
       -------------
Name:  Calvin Cao
Title: President



Date:  August 14, 2007

By:    /s/Daniel Sullivan
       ------------------
Name:  Daniel Sullivan
Title: Chief Financial Officer




                                       23
<PAGE>